CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress. Conference Call and Webcast Information: A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar. About Relmada Therapeutics, Inc. For more information, visit www.relmada.com Investor Contact: Media Inquiries:
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Corporate Communications
media@relmada.com
